@article{2e9811cf470f4463a93afa6aecb4ba3f,
title = "Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease",
abstract = "Although inhibitors of the renin-angiotensin-aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)-related factor 2 activators further reduce this risk is unknown.",
author = "{de Zeeuw}, Dick and Tadao Akizawa and Paul Audhya and Bakris, {George L} and Melanie Chin and Heidi Christ-Schmidt and Angie Goldsberry and Mark Houser and Melissa Krauth and {Lambers Heerspink}, {Hiddo J} and McMurray, {John J} and Meyer, {Colin J} and Hans-Henrik Parving and Giuseppe Remuzzi and Toto, {Robert D} and Vaziri, {Nosratola D} and Christoph Wanner and Janet Wittes and Danielle Wrolstad and Chertow, {Glenn M} and {BEACON Trial Investigators}",
year = "2013",
month = dec,
day = "26",
doi = "10.1056/NEJMoa1306033",
language = "English",
volume = "369",
pages = "2492--503",
journal = "The New England journal of medicine",
issn = "0028-4793",
publisher = "Massachusetts Medical Society",
number = "26",
}